Mañana, JUEVES, 24 DE ABRIL, el sistema se apagará debido a tareas habituales de mantenimiento a partir de las 9 de la mañana. Lamentamos las molestias.
Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents
Author
Guasch, Montserrat; Cañete, Fiorella; Ordás, Ingrid; Iglesisas-Flores, Eva; Clos, Ariadna; Pérez Gisbert, Francisco Javier; Taxonera, Carlos; Vera Mendoza, María Isabel; Mínguez, Miguel; Guardiola, Jordi; Rivero, Montserrat; Nos, Pilar; Gomollón, Fernando; Barrio, Jesús; Francisco, Ruth de; López-Sanromán, Antonio; Martín Arranz, María Dolores; García Planella, Esther; Camargo, Raquel; García-López, Santiago; Castro, Luisa de; Calvet, Xavier; Esteve, María; Mañosa, Miriam; Doménech, EugeniEntity
UAM. Departamento de MedicinaPublisher
WileyDate
2020-04-29Citation
10.1111/jgh.15084
Journal of Gastroenterology and Hepatology 35.12 (2020): 2080-2087
ISSN
0815-9319 (print); 1440-1746 (online)DOI
10.1111/jgh.15084Editor's Version
https://doi.org/10.1111/jgh.15084Subjects
inflammatory bowel disease; surgery; anti‐TNF; immunosuppressants; MedicinaNote
This is the peer reviewed version of the following article: Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. Journal of Gastroenterology and Hepatology (2020): 29 April, which has been published in final form at https://doi.org/10.1111/jgh.15084. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived VersionsRights
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, LtdAbstract
Biological therapies may be changing the natural history of inflammatory bowel diseases, reducing the need for surgical intervention. We aimed to assess whether the availability of anti‐TNF agents impacts the need for early surgery in Crohn's disease (CD) and ulcerative colitis (UC).
Methods
Retrospective, cohort study of patients diagnosed within a 6‐year period before and after the licensing of anti‐TNFs (1990‐1995 and 2007‐2012 for CD; 1995‐2000 and 2007‐2012 for UC) were identified in the ENEIDA Registry. Surgery‐free survival curves were compared between cohorts.
Results
A total of 7,370 CD patients (2,022 in Cohort 1 and 5,348 in Cohort 2) and 8,069 UC patients (2,938 in Cohort 1 and 5,131 in Cohort 2) were included. Immunosuppressants were used significantly earlier and more frequently in both CD and UC post‐biological cohorts. The cumulative probability of surgery was lower in CD following anti‐TNF approval (16% and 11%, 22% and 16%, and 29% and 19%, at 1, 3 and 5 years, respectively p<0.0001), though not in UC (3% and 2%, 4% and 4%, and 6% and 5% at 1, 3 and 5 years, respectively; p=0.2). Ileal involvement, older age at diagnosis and active smoking in CD, and extensive disease in UC, were independent risk factors for surgery, whereas high‐volume IBD centres (in both CD and UC) and immunosuppressant use (in CD) were protective factors.
Conclusions
Anti‐TNF availability was associated with a reduction in early surgery for CD (driven mainly by earlier and more widespread immunosuppressant use) but not in UC
Files in this item
Google Scholar:Guasch, Montserrat
-
Cañete, Fiorella
-
Ordás, Ingrid
-
Iglesisas-Flores, Eva
-
Clos, Ariadna
-
Pérez Gisbert, Francisco Javier
-
Taxonera, Carlos
-
Vera Mendoza, María Isabel
-
Mínguez, Miguel
-
Guardiola, Jordi
-
Rivero, Montserrat
-
Nos, Pilar
-
Gomollón, Fernando
-
Barrio, Jesús
-
Francisco, Ruth de
-
López-Sanromán, Antonio
-
Martín Arranz, María Dolores
-
García Planella, Esther
-
Camargo, Raquel
-
García-López, Santiago
-
Castro, Luisa de
-
Calvet, Xavier
-
Esteve, María
-
Mañosa, Miriam
-
Doménech, Eugeni
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain
Chaparro Sánchez, María; Barreiro-de Acosta, Manuel; Benítez, José Manuel; Cabriada, José Luis; Casanova, María José; Ceballos, Daniel; Esteve, María; Fernández, Hipólito; Ginard, Daniel; Gomollón, Fernando; Lorente, Rufo; Nos, Pilar; Riestra, Sabino; Rivero, Montserrat; Robledo, Pilar; Rodríguez, Cristina; Sicilia, Beatriz; Torrella, Emilio; Garre, Ana; García García-Esquinas, Esther; Rodríguez Artalejo, Fernando; Pérez Gisbert, Francisco Javier
2019-05-01 -
The genetic diversity and dysfunctionality of catalase associated with a worse outcome in crohn’s disease
Iborra, Marisa; Moret, Inés; Busó, Enrique; García-Giménez, José Luis; Ricart, Elena; Pérez Gisbert, Francisco Javier; Cabré, Eduard; Esteve, Maria; Márquez-Mosquera, Lucía; García-Planella, Esther; Guardiola, Jordi; Pallardó, Federico V.; Serena, Carolina; Algaba-Chueca, Francisco; Domènech, Eugeni; Nos, Pilar; Beltrán, Belén
2022-12-14